BChE-IN-44
BChE-IN-44 is a potent, brain-penetrant, highly selective BChE inhibitor [equine BChE IC50 = 18.00 pM, human BChE IC50 = 1.50 nM]. BChE-IN-44 shows neuroprotective effects against the Aβ1-42-induced injury model and inhibitory effects on Aβ1-42 self-aggregation. BChE-IN-44 reduces the levels of inflammatory factors (NO, IL-6, and TNF-α) in Lipopolysaccharides (HY-D1056)-induced BV2 cells. BChE-IN-44 can significantly ameliorate Scopolamine (HY-N0296)-induced cognition impairment. BChE-IN-44 exhibits capacity in the regulation of BChE and acetylcholine levels in the mouse hippocampus. BChE-IN-44 can be used for the study of Alzheimer’s disease (AD).
For research use only. We do not sell to patients.
- Formula: C22H23N3O4
- Molecular Weight:393.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-6 |
RatBuChE |
BChE-IN-44 (Compound N14) (50 μM, 24 h) lead to about 15 % cell toxicity in PC12 and SH-SY5Y, suggesting that BChE-IN-44 possesses a high safety profile in vitro[1].
BChE-IN-44 shows a Kc of 0.017 μM, indicating that BChE-IN-44 possesses a higher affinity for BChE[1].
BChE-IN-44 (5-20 μM, 24 h) significantly reduces the levels of inflammatory factors (NO, IL-6, and TNF-α) in Lipopolysaccharides (LPS)-induced BV2 cells[1].
BChE-IN-44 (20 μM, 24 h) demonstrates significant neuroprotective efficacy against Aβ1–42-induced injury in PC12 cells[1].
BChE-IN-44 (20 μM, 48 h) effectively inhibits Aβ1-42 aggregation, confirming the good inhibitory effects of the carrier scaffold on Aβ1–42 aggregation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC12 cells, SH-SY5Y cells
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Led to about 15 % cell toxicity in PC12 and SH-SY5Y.
-
Cell Line:BV2 cells
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the levels of inflammatory factors (NO, IL-6, and TNF-α) in LPS-induced BV2 cells.
-
Cell Line:PC12 cells
-
Concentration:20 nM
-
Incubation Time:24 h
-
Result:Showed significant neuroprotective efficacy against Aβ1-42-induced injury in PC12 cells.
| Species | Dose | Route | AUC0-t | MRT0-t | T1/2 | Cmax | Tmax | F |
|---|---|---|---|---|---|---|---|---|
| Rat | 5 mg/kg | i.v. | 9.94 μg·h/mL | 0.75 h | 3.1 h | 27.87 μg/mL | 0.033 h | / |
| Rat | 50 mg/kg | i.p. | 16.36 μg·h/mL | 2.57 h | 4.43 h | 12.93 μg/mL | 0.25 h | 16.46 % |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Thirty-six six-week-old male Kunming mice (weighing 25-30 g) were intraperitoneally injected with scopolamine (3 mg/kg) to mimic AD-like cognitive deficits[1].
-
Dosage:5 mg/kg, 10 mg/kg, 20 mg/kg
-
Administration:I.p., once daily for 14 days, 30 mins after Scopolamine
-
Result:Increased the spontaneous alternation rate to 72.6%, indicating improved working memory.
Increased central region dwell time and travel distance, and reduced anxiety-like behaviors.
Shortened escape latency, reduced travel distance, and increased platform crossings, showing improved spatial learning memory.
Behavioral trajectory plots showed more organized.
Increases ACh levels and decreases AChE and BChE activities.
Reduces IL-6 and TNF-α levels and inhibits neuroinflammation.
Chemical Information
-
Molecular Weight 393.44
-
Formula C22H23N3O4
-
SMILES
CC1=CC(O)=C(C=C1)C(NCCC2=CNC3=CC=C(C=C23)OC(N4CCC4)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz